These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 31174840)

  • 1. ADAR and Immune Silencing in Cancer.
    Herbert A
    Trends Cancer; 2019 May; 5(5):272-282. PubMed ID: 31174840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mendelian disease caused by variants affecting recognition of Z-DNA and Z-RNA by the Zα domain of the double-stranded RNA editing enzyme ADAR.
    Herbert A
    Eur J Hum Genet; 2020 Jan; 28(1):114-117. PubMed ID: 31320745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Z-DNA and Z-RNA in human disease.
    Herbert A
    Commun Biol; 2019; 2():7. PubMed ID: 30729177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An ADAR1 dsRBD3-PKR kinase domain interaction on dsRNA inhibits PKR activation.
    Sinigaglia K; Cherian A; Du Q; Lacovich V; Vukić D; Melicherová J; Linhartova P; Zerad L; Stejskal S; Malik R; Prochazka J; Bondurand N; Sedláček R; O'Connell MA; Keegan LP
    Cell Rep; 2024 Aug; 43(8):114618. PubMed ID: 39146181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adenosine deaminase acting on RNA (ADAR1), a suppressor of double-stranded RNA-triggered innate immune responses.
    Samuel CE
    J Biol Chem; 2019 Feb; 294(5):1710-1720. PubMed ID: 30710018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ADAR and hnRNPC deficiency synergize in activating endogenous dsRNA-induced type I IFN responses.
    Herzner AM; Khan Z; Van Nostrand EL; Chan S; Cuellar T; Chen R; Pechuan-Jorge X; Komuves L; Solon M; Modrusan Z; Haley B; Yeo GW; Behrens TW; Albert ML
    J Exp Med; 2021 Sep; 218(9):. PubMed ID: 34297039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interplay between A-to-I Editing and Splicing of RNA: A Potential Point of Application for Cancer Therapy.
    Goncharov AO; Shender VO; Kuznetsova KG; Kliuchnikova AA; Moshkovskii SA
    Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New Insights into the Biological Role of Mammalian ADARs; the RNA Editing Proteins.
    Mannion N; Arieti F; Gallo A; Keegan LP; O'Connell MA
    Biomolecules; 2015 Sep; 5(4):2338-62. PubMed ID: 26437436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functionally distinct double-stranded RNA-binding domains associated with alternative splice site variants of the interferon-inducible double-stranded RNA-specific adenosine deaminase.
    Liu Y; George CX; Patterson JB; Samuel CE
    J Biol Chem; 1997 Feb; 272(7):4419-28. PubMed ID: 9020165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ADAR proteins: double-stranded RNA and Z-DNA binding domains.
    Barraud P; Allain FH
    Curr Top Microbiol Immunol; 2012; 353():35-60. PubMed ID: 21728134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double-stranded RNA-specific adenosine deaminase: nucleic acid binding properties.
    Liu Y; Herbert A; Rich A; Samuel CE
    Methods; 1998 Jul; 15(3):199-205. PubMed ID: 9735305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In cancer, A-to-I RNA editing can be the driver, the passenger, or the mechanic.
    Ganem NS; Ben-Asher N; Lamm AT
    Drug Resist Updat; 2017 May; 32():16-22. PubMed ID: 29145975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A-to-I RNA editing - thinking beyond the single nucleotide.
    Ganem NS; Lamm AT
    RNA Biol; 2017 Dec; 14(12):1690-1694. PubMed ID: 28820319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-derived IFN triggers chronic pathway agonism and sensitivity to ADAR loss.
    Liu H; Golji J; Brodeur LK; Chung FS; Chen JT; deBeaumont RS; Bullock CP; Jones MD; Kerr G; Li L; Rakiec DP; Schlabach MR; Sovath S; Growney JD; Pagliarini RA; Ruddy DA; MacIsaac KD; Korn JM; McDonald ER
    Nat Med; 2019 Jan; 25(1):95-102. PubMed ID: 30559422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DHX9 suppresses RNA processing defects originating from the Alu invasion of the human genome.
    Aktaş T; Avşar Ilık İ; Maticzka D; Bhardwaj V; Pessoa Rodrigues C; Mittler G; Manke T; Backofen R; Akhtar A
    Nature; 2017 Apr; 544(7648):115-119. PubMed ID: 28355180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zalpha-domains: at the intersection between RNA editing and innate immunity.
    Athanasiadis A
    Semin Cell Dev Biol; 2012 May; 23(3):275-80. PubMed ID: 22085847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. All I's on the RADAR: role of ADAR in gene regulation.
    Shevchenko G; Morris KV
    FEBS Lett; 2018 Sep; 592(17):2860-2873. PubMed ID: 29770436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ADARs and editing: The role of A-to-I RNA modification in cancer progression.
    Fritzell K; Xu LD; Lagergren J; Öhman M
    Semin Cell Dev Biol; 2018 Jul; 79():123-130. PubMed ID: 29146145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How does RNA editing affect dsRNA-mediated gene silencing?
    Bass BL
    Cold Spring Harb Symp Quant Biol; 2006; 71():285-92. PubMed ID: 17381308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A third member of the RNA-specific adenosine deaminase gene family, ADAR3, contains both single- and double-stranded RNA binding domains.
    Chen CX; Cho DS; Wang Q; Lai F; Carter KC; Nishikura K
    RNA; 2000 May; 6(5):755-67. PubMed ID: 10836796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.